若年性特発性関節炎(ステイル病)(Idiopathic Juvenile Arthritis (Still’s Disease))：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Idiopathic Juvenile Arthritis (Still’s Disease) Overview 7
Therapeutics Development 8
Pipeline Products for Idiopathic Juvenile Arthritis (Still’s Disease) – Overview 8
Pipeline Products for Idiopathic Juvenile Arthritis (Still’s Disease) – Comparative Analysis 9
Idiopathic Juvenile Arthritis (Still’s Disease) – Therapeutics under Development by Companies 10
Idiopathic Juvenile Arthritis (Still’s Disease) – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Idiopathic Juvenile Arthritis (Still’s Disease) – Products under Development by Companies 15
Idiopathic Juvenile Arthritis (Still’s Disease) – Companies Involved in Therapeutics Development 16
AlphaMab Co., Ltd 16
Biocon Limited 17
Epirus Biopharmaceuticals, Inc. 18
Genor BioPharma Co., Ltd. 19
Mabion SA 20
Oncodesign SA 21
Panacea Biotec Limited 22
Pfizer Inc. 23
Sandoz International GmbH 24
Swedish Orphan Biovitrum AB 25
UCB S.A. 26
Idiopathic Juvenile Arthritis (Still’s Disease) – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
abatacept biosimilar – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
adalimumab biosimilar – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
adalimumab biosimilar – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
adalimumab biosimilar – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
adalimumab biosimilar – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
adalimumab biosimilar – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
adalimumab biosimilar – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
anakinra (recombinant) – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
certolizumab pegol – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
etanercept biosimilar – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
etanercept biosimilar – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
etanercept biosimilar – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
etanercept biosimilar – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecules to Inhibit RIP2 for Crohn’s Disease and Polyarthritis – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
tofacitinib – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Idiopathic Juvenile Arthritis (Still’s Disease) – Recent Pipeline Updates 60
Idiopathic Juvenile Arthritis (Still’s Disease) – Dormant Projects 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75